Subcutaneous administration CpG-ODNs acts as a potent adjuvant for an HIV-1-tatbased vaccine candidate to elicit cellular immunity in BALB/c
Objective To evaluate the combined effects of CpG oligodeoxynucleotides (CpG-ODNs) adjuvant and subcutaneous injection route on efficacy of a HIV-1- tat DNA vaccine candidate using BALB/c mice as an animal model. Results Evaluation of cellular and humoral immunity of mice injected subcutaneously with HIV-1-tat gene cloned into a pcDNA3.1 vector indicated that significant levels of IFN-c cytokine secretion (900 pg/ ml), lymphocyte proliferation (2.5 stimulation index) and IgG2a (1.45 absorbance 450 nm) production could be achieved. These indicators of stimulated cellular immunity were elicited 2 weeks after the last injection (P\0.05). Conclusions Formulation of HIV-1-tat DNA vaccine candidate with CpG-ODNs as an adjuvant while administrated subcutaneously are a promising approach to induce effective cellular immunity responses against HIV-1 infection
Read More